Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00303433 · ClinicalTrials.gov registry record · Phase 4
Namenda to Prevent Post-Operative Delirium
A Phase 4 study, sponsored by University of Rochester.
- Terminated
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT00303433: Clinical Trial Phase 4 study, sponsored by University of Rochester.
NCT00303433 is a Phase 4 study that was terminated before completion, run by University of Rochester. The registered enrollment target is 30 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00303433, a Phase 4 study, was terminated before completion, sponsored by University of Rochester.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
Post Operative Delirium is a common and serious risk of surgery. Delirium, when it occurs is associated with an increased risk of mortality, increase length of stay, and more adverse outcomes in general, including increased risk of higher level of care required at discharge. Namenda, which is currently approved for moderate or severe Alzheimer's disease has a unique mechanism of action than other drugs for this condition. It may have the ability to protect the brain from more severe consequences of hypoxia, or hypoglycemia. Hence it is being looked at in this study to see if it can reduce the incidence and/or severity of delirium post-operatively.
Interventions
- DRUG Namenda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-03 |
| Est. Completion | 2006-09 |
| Phase | Phase 4 |
Why NCT00303433 stopped before completion
NCT00303433 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which Namenda is the first listed.
NCT00303433 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00303433 about?
NCT00303433 is a clinical study titled "Namenda to Prevent Post-Operative Delirium". Post Operative Delirium is a common and serious risk of surgery. Delirium, when it occurs is associated with an increased risk of mortality, increase length of stay, and more adverse outcomes in general, including increased risk of higher level of care required at discharge. Namenda, which is curre...
What is the current status of trial NCT00303433?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2006-03. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00303433?
The interventions under investigation include: Namenda (DRUG).
Who is sponsoring clinical trial NCT00303433?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00303433's enrollment target sits among peer trials
30 1552nd of 2000 higher than 367 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia